|
Jan 12
|
Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now?
|
|
Dec 31
|
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
|
|
Dec 31
|
Is Intellia Therapeutics, Inc. (NASDAQ:NTLA) Trading At A 25% Discount?
|
|
Dec 27
|
13 Most Promising Future Stocks To Buy According To Hedge Funds
|
|
Nov 28
|
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
|
|
Oct 6
|
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
|
|
Oct 5
|
This Market-Beating Stock Just Gave Investors More Reasons to Invest
|
|
Oct 4
|
Intellia (NTLA), Regeneron Expand Deal for Gene-Editing Therapies
|
|
Oct 4
|
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) have lost 51%, as stock drops 8.3% this past week
|
|
Oct 3
|
Intellia Therapeutics Could Rise 167%, Per Wall Street, But Is It a Buy?
|
|
Oct 3
|
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
|
|
Aug 4
|
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
|